Hepion director files initial ownership report

Hepion Pharmaceuticals, Inc. filed an initial ownership report for director Appajosyula Sireesh on Form 3.

Accepted by SEC EDGAR 03/18/2026 - 05:20 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. filed an initial ownership report for director Appajosyula Sireesh on Form 3. The filing shows no reportable transactions and no derivative positions, with all buy, sell, acquire, and dispose counts and related share amounts reported as zero.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing for Hepion Pharmaceuticals (HEPA) show for Appajosyula Sireesh?

The Form 3 shows that director Appajosyula Sireesh has no reportable transactions or derivative positions. All buy, sell, acquire, dispose, exercise, gift, tax withholding, and restructuring share counts are reported as zero in this initial ownership report.

Are there any buy or sell transactions reported for Hepion (HEPA) director Appajosyula Sireesh on this Form 3?

No transactions are reported for Appajosyula Sireesh. The transaction summary lists buyCount, sellCount, acquireCount, disposeCount, and otherCount all as zero, with netBuySellShares also zero, indicating no trading activity in this filing.

Does Hepion Pharmaceuticals (HEPA) disclose any option exercises or derivative positions for Appajosyula Sireesh?

No derivative activity is disclosed for Appajosyula Sireesh. The exerciseCount, exerciseShares, and derivativeTransactionCount are all zero, and the derivativeSummary is empty, indicating no reported options, warrants, or similar derivative holdings in this Form 3 excerpt.

Are there any gifts or tax-withholding share movements reported for Hepion (HEPA) director Appajosyula Sireesh?

The Form 3 reports no gifts or tax-related share movements. GiftCount, giftShares, taxWithholdingCount, and taxWithholdingShares are all zero, showing no gifts or shares withheld for taxes associated with Appajosyula Sireesh in this filing data.

Does the Hepion (HEPA) Form 3 show any restructuring-related share transfers for Appajosyula Sireesh?

No restructuring-related share transfers are shown. The restructuringCount and restructuringShares fields are both zero, and netBuySellDirection is listed as neutral, indicating no entity restructurings or similar movements reported for Appajosyula Sireesh here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Appajosyula Sireesh

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/16/2026

3. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Sireesh Appajosyula	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)